Free Trial
NASDAQ:ALPN

Alpine Immune Sciences (ALPN) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$64.97
$64.97
50-Day Range
$64.37
$64.97
52-Week Range
$8.33
$65.00
Volume
640 shs
Average Volume
1.92 million shs
Market Capitalization
$4.46 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$52.33
ALPN stock logo

About Alpine Immune Sciences Stock (NASDAQ:ALPN)

Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.

ALPN Stock News Headlines

What 11 Analyst Ratings Have To Say About Alpine Immune Sciences
[URGENT] Altcoin Winning Picks
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
Alpine Immune Sciences Inc
[URGENT] Altcoin Winning Picks
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
Alpine Immune Sciences, Inc. (ALPN)
See More Headlines
Receive ALPN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alpine Immune Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/09/2024
Today
7/20/2024
Next Earnings (Estimated)
8/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ALPN
Employees
142
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$52.33
High Stock Price Target
$65.00
Low Stock Price Target
$18.00
Potential Upside/Downside
-19.5%
Consensus Rating
Hold
Rating Score (0-4)
2.27
Research Coverage
11 Analysts

Profitability

Net Income
$-32,180,000.00
Pretax Margin
-64.99%

Debt

Sales & Book Value

Annual Sales
$56.52 million
Book Value
$4.85 per share

Miscellaneous

Free Float
39,581,000
Market Cap
$4.46 billion
Optionable
Optionable
Beta
0.97
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Mitchell H. Gold M.D. (Age 56)
    Executive Chairman & CEO
    Comp: $778.2k
  • Dr. Stanford Peng M.D. (Age 53)
    Ph.D., President and Head of Research & Development
    Comp: $751.2k
  • Mr. Paul Rickey (Age 45)
    Senior VP, CFO, Treasurer & Secretary
    Comp: $577.1k
  • Ms. M. Christina Yi (Age 47)
    Chief Technology Officer
  • Temre Johnson
    Head of IR & Corporate Communications
  • Dr. Remy Durand Ph.D. (Age 39)
    Chief Business Officer
  • Dr. Wolfgang Dummer M.D. (Age 58)
    Ph.D., Chief Medical Officer

ALPN Stock Analysis - Frequently Asked Questions

How were Alpine Immune Sciences' earnings last quarter?

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) released its quarterly earnings data on Thursday, May, 9th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.15. The biotechnology company earned $7.03 million during the quarter, compared to the consensus estimate of $5.50 million. Alpine Immune Sciences had a negative net margin of 65.17% and a negative trailing twelve-month return on equity of 14.86%.

What other stocks do shareholders of Alpine Immune Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Alpine Immune Sciences investors own include Viking Therapeutics (VKTX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), Abeona Therapeutics (ABEO), CymaBay Therapeutics (CBAY), Genocea Biosciences (GNCA) and OPKO Health (OPK).

This page (NASDAQ:ALPN) was last updated on 7/21/2024 by MarketBeat.com Staff

From Our Partners